- Home
- VMD vs ATAI Comparison
VMD vs ATAI Comparison
Compare VMD & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VMD | ATAI |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.5M | 1.4B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | VMD | ATAI |
|---|---|---|
| Price | $7.56 | $4.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 149.0K | ★ 3.2M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.92 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $254,794,000.00 | $3,018,000.00 |
| Revenue This Year | $20.05 | $943.18 |
| Revenue Next Year | $17.44 | N/A |
| P/E Ratio | $21.91 | ★ N/A |
| Revenue Growth | 18.89 | ★ 811.78 |
| 52 Week Low | $5.93 | $1.15 |
| 52 Week High | $8.62 | $6.75 |
Technical Indicators
Market Signals| Indicator | VMD | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 66.45 | 42.99 |
| Support Level | $7.24 | $3.88 |
| Resistance Level | $7.36 | $4.72 |
| Average True Range (ATR) | 0.20 | 0.24 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 87.26 | 13.10 |
Price Performance
Historical ComparisonAbout VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.